Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
about
Targeting Cell Survival Proteins for Cancer Cell DeathKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaRational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Potential utility of the pan-Bcl-2 inhibitor GX15-070 (obatoclax) in cancer immunotherapy.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyBeyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitroTarget mRNA inhibition by oligonucleotide drugs in man.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesAn evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesTargeting cell death signaling in colorectal cancer: current strategies and future perspectives.Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.Apoptosis inducers in chronic lymphocytic leukemia.New dimension in therapeutic targeting of BCL-2 family proteins.Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.Novel agents in indolent lymphomas.Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments.BH3 Mimetics for the Treatment of Prostate Cancer.Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of Proapoptotic Peptides.Synthesis, Molecular Structure, Anticancer Activity, and QSAR Study of N-(aryl/heteroaryl)-4-(1H-pyrrol-1-yl)Benzenesulfonamide Derivatives.
P2860
Q26765447-5C77FCC6-0EDD-441B-A670-52A6B0B1C434Q26781895-0C9D674D-AB00-46B0-AEF5-1F7610685073Q33840360-17E13374-E7C7-450D-B1DE-739FEAC7DB9FQ33940448-479DF84A-9CAD-4496-884F-B67EA7D5588AQ34004454-1956DF42-C659-46FA-AB79-CCE1CC729DFCQ35009440-23E64114-C0B3-49E0-A534-826E40C23C8EQ36435109-313FFFD9-67A3-4182-BE00-7361491A0922Q36602853-82EB89B8-4534-4C4F-B1AC-7B38EA5B0BA4Q36696524-D343D44A-336C-45F1-B851-71D4B7097A5FQ37602717-21EB06ED-D475-42E5-B3CD-65D7B31796A5Q37707092-E2D7BEA1-2981-4426-A887-8399C25AD6B3Q38187815-DD0E5583-CF71-4C29-B075-4FEA7CACC142Q38477617-EF8CB376-19C3-465B-B6AF-57CEA89B2D6EQ38999607-020BCF3A-CF33-486E-AB97-AA6E8E589995Q39431412-E5D3FCD3-A070-4093-BB57-5D8F61D9B1F8Q40051547-FE468714-9BE7-4CBA-BD86-323243ED6126Q41463153-86D300CD-B4D1-462E-8A08-3001E31AD6D6Q48145247-8C39D74F-7BA0-4BFA-B485-633A03843698Q54975597-F2E06AEE-17DC-4F31-ADBA-D0605684198E
P2860
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
@en
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
@nl
type
label
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
@en
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
@nl
prefLabel
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
@en
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
@nl
P2860
P1476
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
@en
P2093
David Claxton
Jamal Joudeh
P2860
P304
P356
10.1517/13543784.2012.652302
P407
P577
2012-02-11T00:00:00Z